

*[P-551E] Outcomes associated with proton pump inhibitor (PPI) step down therapy*

*Jun, H., Lim, K., VA Greater Los Angeles Healthcare System, West Los Angeles, 11301 Wilshire Blvd., Los Angeles, CA, USA and Geriatric Pharmacy Practice Residency (DUE), VAGLA Healthcare System, Los Angeles, CA 90073, USA*

*To investigate the patient and pharmacoeconomic outcomes of the step down proton-pump inhibitor (PPI) therapy in the patients who will be converted from lansoprazole 30 mg BID to lansoprazole 30 mg QD with or without an H2 receptor blocker. With an increased use and relatively high drug acquisition cost, PPI expenditures have increased at the Veterans Affairs Great Los Angeles Health System (VAGLAHS) and is approaching \$1.2 million a year. VISN22 has implemented new PPI restriction approved by Pharmacy & Therapeutics (P&T) and Gastroenterology department. A list of patients who have been on lansoprazole 30 mg twice a day dosing for more than 60 days was generated. Prescribing physicians were contacted via e-mail and telephone and informed of the dosing change. Patients were switched to the PPI regimen of 30 mg once daily with the consent of their physicians per P&T guideline. If patients fail the QD dosing, their provider continued to follow the guidelines. Follow up phone calls were made approximately 4 to 6 weeks after the switch. Patients were asked about GI symptoms and tolerability of medication. The results will be collected and evaluated by the investigators to determine if the QD dosing of lansoprazole is effective, safe and economic.*